ONCLIVE NEWS NETWORK: ON LOCATION WILL BE LIVE AT ESMO THIS WEEK - STAY TUNED FOR MORE INFORMATION!

Dr. Valdes-Albini on the FDA Approval of Adjuvant Pertuzumab in HER2+ Breast Cancer

Frances Valdes-Albini, MD
Published: Thursday, Apr 12, 2018



Frances Valdes-Albini, MD, assistant professor of clinical medicine, Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses the FDA approval of adjuvant pertuzumab (Perjeta) in patients with HER2-positive breast cancer.

The data on adjuvant pertuzumab were presented at the 2018 ASCO Annual Meeting. The benefit seemed to be restricted to patients with node-positive disease. Therefore, pertuzumab in combination with trastuzumab (Herceptin) and chemotherapy should be considered as a treatment for patients with node-positive disease and perhaps in patients with hormone receptor-negative disease, states Valdes-Albini.

It will be interesting to see how this plays a role in patients who have received neoadjuvant therapy, says Valdes-Albini. A lot of physicians are offering dual blockade in the neoadjuvant setting, but the study doesn’t address the impact of adjuvant dual blockade in patients who have received neoadjuvant treatment.
 


Frances Valdes-Albini, MD, assistant professor of clinical medicine, Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses the FDA approval of adjuvant pertuzumab (Perjeta) in patients with HER2-positive breast cancer.

The data on adjuvant pertuzumab were presented at the 2018 ASCO Annual Meeting. The benefit seemed to be restricted to patients with node-positive disease. Therefore, pertuzumab in combination with trastuzumab (Herceptin) and chemotherapy should be considered as a treatment for patients with node-positive disease and perhaps in patients with hormone receptor-negative disease, states Valdes-Albini.

It will be interesting to see how this plays a role in patients who have received neoadjuvant therapy, says Valdes-Albini. A lot of physicians are offering dual blockade in the neoadjuvant setting, but the study doesn’t address the impact of adjuvant dual blockade in patients who have received neoadjuvant treatment.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Community Practice Connections: Oncology Best Practice™ Targeting Cell Cycle Progression: The Latest Advances on CDK4/6 Inhibition in Metastatic Breast CancerOct 31, 20181.0
Publication Bottom Border
Border Publication
x